InsidersTradesSigma
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
无可用的信号评分。
Discover the full record of transactions filed by Nunn Jason Raleigh. Officer active across 3 companies, notably Regulus Therapeutics Inc.. Aggregated, 6 disclosures have been published. Split: 1 buy · 0 sell. Total volume traded: €1m. Activity tracked since 30 April 2025. The latest transaction was filed on 2 September 2026 (Disposition). Regulator: SEC (Form 4). All data is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 条申报中的 6 条
Nunn Jason Raleigh is a declarant linked to Zenas BioPharma, Inc. and Regulus Therapeutics Inc., where he is a director. Across 4 filings, the recent filings held run from 2024-09-16 to 2025-10-14, with EUR 1037486 of buys and EUR 0 of sells in that recent sample, and the modal transaction nature is Acquisition.